A technology commercialisation strategy should convert scientific potential into a focused and realistic development pathway. Scientific teams often identify several possible applications for a new technology, but each option may require different evidence, capabilities, partners, timelines and levels of funding. The central challenge is therefore not simply to demonstrate what the technology can do, but to decide where limited resources can create the strongest technical and commercial progress.

Scientific feasibility is not the same as commercial viability

A scientifically feasible application may still be commercially unattractive. The addressable market may be too small, customer demand may be unclear, the regulatory pathway may be disproportionate or the required development investment may exceed the realistic value of the opportunity.

Commercial viability should therefore be assessed alongside scientific feasibility from an early stage. This does not mean allowing short-term market considerations to replace scientific judgement. It means understanding which applications can create a credible route towards customer value, partnerships, funding and sustainable business development.

Start with the problem the technology can solve

Technology-led projects often begin with the capabilities of the underlying platform. Commercial decisions, however, need to begin with a clearly defined problem. Who experiences the problem? How important is it? How is it currently addressed? What improvement would justify changing an established process, product or supplier?

A strong technology commercialisation strategy connects the scientific capability to a specific use case and an identifiable customer group. The clearer this connection becomes, the easier it is to assess the required performance, supporting evidence, development priorities and potential route to market.

Compare applications before committing development resources

When several applications appear possible, they should be compared using the same decision criteria. These may include the importance of the customer problem, technical fit, development effort, regulatory complexity, competitive differentiation, time to initial validation, funding requirements and access to relevant customers or partners.

The purpose is not to calculate a theoretically perfect ranking. It is to make the assumptions behind each option visible and to identify which applications offer the most credible balance between scientific potential, commercial relevance and practical feasibility. A technology commercialisation strategy should make these assumptions explicit and provide a transparent basis for prioritising applications.

This comparison can also reveal that different applications should be pursued in sequence. A nearer-term research-use application, for example, may create technical validation, customer feedback or initial revenue while a more complex therapeutic pathway continues to develop.

Define the evidence required for each commercial pathway

Different applications require different forms of evidence. A potential customer may need performance data under realistic operating conditions. An industry partner may require reproducibility, scalability or compatibility with an existing workflow. An investor may focus on intellectual property, market potential, regulatory risk and the milestones required to reach the next financing stage.

The evidence plan should therefore be linked to the intended commercial decision. Additional experiments, prototypes or validation studies are most valuable when they resolve a specific uncertainty that affects customer adoption, partnering, funding or further development.

Align scientific milestones with commercial objectives

Scientific development plans are often organised around technical work packages. A commercialisation pathway requires an additional perspective: which milestone will enable the next important business decision?

A milestone may be intended to confirm technical performance, demonstrate relevance to a priority application, support a pilot customer discussion, enable a development partnership or strengthen a financing case. Making this purpose explicit helps the team concentrate limited resources on the work that creates the greatest strategic value. This ensures that the technology commercialisation strategy connects technical progress with the decisions required for partnering, funding and market development.

This alignment also improves communication between scientists, founders, management teams, investors and external partners. Each group can understand not only what is being developed, but why the next development step matters.

Decide which commercialisation route fits the technology

The appropriate route depends on the technology, application, development stage and capabilities of the organisation. Some technologies can support a direct product strategy. Others may be better suited to licensing, co-development, service models, research-use products, strategic partnerships or the preparation of a dedicated spin-off.

The decision should consider more than theoretical value creation. It should also reflect the organisation’s ability to finance development, manage regulatory and quality requirements, build commercial capabilities, protect intellectual property and support customers over time. WIPO also provides practical guidance on knowledge and technology transfer, including commercialisation through licensing, partnerships and spin-outs.

A realistic route is one that matches the opportunity with the resources and capabilities that can actually be mobilised.

Use partners to close capability and market-access gaps

Scientific teams and young companies rarely possess every capability required for commercialisation. Relevant gaps may include application expertise, regulatory knowledge, product development, manufacturing, quality management, access to pilot customers, business development or commercial leadership.

Partners should be selected according to the specific contribution required at the current stage. The objective is not to build the largest possible network, but to identify organisations and individuals who can provide concrete technical, market or commercial value.

Well-prepared partner discussions begin with a clear proposition: the problem being addressed, the role of the technology, the evidence already available, the remaining uncertainties and the form of collaboration being considered.

Build a focused technology commercialisation strategy

A focused technology commercialisation strategy brings together the priority application, target customer, required evidence, development milestones, commercial route, partner requirements and resource assumptions. It should provide a practical sequence of decisions rather than an abstract description of market potential.

The strategy should also remain adaptable. Customer discussions, scientific results, partner feedback and regulatory findings may change the relative attractiveness of different options. Regular review allows the team to refine priorities without losing the overall direction.

The objective is not to pursue every scientifically interesting possibility. It is to create a credible pathway from scientific promise to technical validation, commercial relevance and sustainable further development.

About the author

Dr. Arnold Martin is the founder of TrueNorth Loyaris and advises life sciences companies, scientific start-up teams and technology-driven organisations on EMEA market entry, scalable growth and technology commercialisation. His work combines scientific understanding with practical experience in biotechnology development, business development, partnerships, financing and operational leadership.

Learn more about Dr. Arnold Martin

Discussing your technology commercialisation priorities

A focused conversation can help clarify priority applications, development milestones, commercial pathways and the partners required for the next stage.

Discuss your commercialisation priorities